anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by formulaII(R is quinolyl, benzotriazolyl, alpha-lower alkylbenzylideneimino or pteridino). EXAMPLE:23-O-(8-Quinolyl)mycaminosyltylonolide. USE:An antimicrobial agent against Gram-positive and Gram-negative bacteria capable of exhibiting powerful activity particularly against Gram-positive bacteria. PREPARATION:A mycaminosyltylonolide derivative, expressed by formula II (A is protected aldehyde), and having protected aldehyde is reacted with a compound expressed by formula III, preferably in the presence of a condensing agent, e.g. triphenylphosphine, in a solvent, e.g. tetrahydrofuran (THF), usually at room temperature to give a compound expressed by formula IV. The protecting group of the aldehyde is then removed.
PURPOSE: A composition for treating cancer and a cancer therapeutic method using an antibody which binds to ECM1 protein are provided to suppress cancer cell growth, to ensure anticancer effect, and to prevent, relieve, and treat HER2-associated diseases. CONSTITUTION: A composition for anticancer contains an antibody which binds to ECM(extracellular matrix) 1 protein as an active ingredient. The antibody suppresses cell proliferation and induces cell apoptosis. The ECM1 protein has an amino acid sequence of sequence number 1. The antibody recognizes an internal site or an N terminal site of ECM1. The cancer includes ovarian cancer, peritoneal cancer, fallopian tube cancer, breast cancer, non-small cell lung cancer(NSCLC), squamous cell carcinoma, prostate cancer, or colon cancer.
Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children, and despite considerable progress in treatment outcomes, relapses still pose significant risks of mortality and long-term complications. To address this challenge, we employed a supervised machine learning technique, specifically random survival forests, to predict the risk of relapse and mortality using array-based DNA methylation data from a cohort of 763 pediatric ALL patients treated in Nordic countries. The relapse risk predictor (RRP) was constructed based on 16 CpG sites, demonstrating c-indexes of 0.667 and 0.677 in the training and test sets, respectively. The mortality risk predictor (MRP), comprising 53 CpG sites, exhibited c-indexes of 0.751 and 0.754 in the training and test sets, respectively. To validate the prognostic value of the predictors, we further analyzed two independent cohorts of Canadian (n = 42) and Nordic (n = 384) ALL patients. The external validation confirmed our findings, with the RRP achieving a c-index of 0.667 in the Canadian cohort, and the RRP and MRP achieving c-indexes of 0.529 and 0.621, respectively, in an independent Nordic cohort. The precision of the RRP and MRP models improved when incorporating traditional risk group data, underscoring the potential for synergistic integration of clinical prognostic factors. The MRP model also enabled the definition of a risk group with high rates of relapse and mortality. Our results demonstrate the potential of DNA methylation as a prognostic factor and a tool to refine risk stratification in pediatric ALL. This may lead to personalized treatment strategies based on epigenetic profiling.
Socioeconomic status and smoking are reportedly associated with underweight and obesity; however, their associations among pregnant women are unknown. This study aimed to investigate whether socioeconomic factors, namely educational attainment, household income, marital status, and employment status, were associated with pre-pregnancy body mass index (BMI) categories, including severe-moderate underweight (BMI ≤ 16.9 kg/m2), mild underweight (BMI, 17.0-18.4 kg/m2), overweight (BMI, 25.0-29.9 kg/m2), and obese (BMI ≥ 30.0 kg/m2) among Japanese pregnant women using data from the Japan Environment and Children's Study (JECS). In total, pregnant women were included 96,751. Age- and parity-adjusted multivariable multinomial logistic regression analyses assessed socioeconomic factors and smoking associations with falling within abnormal BMI categories (normal BMI as the reference group). Lower education and lower household were associated with overweight and obesity, and, especially, lowest education and household income had relatively higher point estimate relative ratios (RRs) of 3.97 and 2.84, respectively. Regarding the risks for underweight, however, only junior high school education had a significantly higher RR for severely to moderately underweight. Regarding occupational status, homemakers or the unemployed had a higher RR for severe-moderate underweight, overweight, and obesity. Unmarried, divorced, or bereaved women had significantly higher RRs for mildly underweight status. Quitting smoking early in pregnancy/still smoking had higher RRs for all four not having normal BMI outcomes; however, quitting smoking before pregnancy had a higher RR only for obese individuals. Lower educational attainment and smoking are essential intervention targets for obesity and severe-moderate underweight prevention in younger women. Lower household income is also a necessary target for obesity.
In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
NEW MATERIAL:The 1-substituted-azacycloheptan-2-one of formula I (m is integer of 1-4). EXAMPLE:1-(3,7-Dimethyl-2,6-octadienyl)azacycloheptan-2-one. USE:A transcutaneous absorbefacient for drug. It has high safety and gives excellent feeling to the body. PREPARATION:The compound of formula I can be produced by reacting azacycloheptan-2-one with a halide of formula II (X is halogen) in the presence of a base such as sodium hydride usually in an inert gas atmosphere under anhydrous condition in a hydrocarbon solvent (e.g. dried toluene at a temperature between room temperature and the refluxing temperature.
BACKGROUND AND OBJECTIVE: Cutaneous squamous cell carcinoma (cSCC) is the second leading cause of skin cancer mortality in Europe. Few studies have analyzed the different pathways of this tumor progression in its natural history. The main objective of this study was to analyze the different metastatic and progression pathways and their temporal occurrence in the evolution of cSCC.
MATERIAL AND METHOD: We conducted a multicenter, retrospective, and observational study of consecutive high-risk sSCCs included in the SQUAMATA project.
RESULTS: A total of 222 out of the 1346 patients included relapsed. The most frequent route of progression was the lymphatic one (62.6%). A total of 20.2% of the cases with lymphatic progression developed distant metastases. Only 1 case (3.1%) of distant metastasis followed local recurrence without previous lymphatic metastasis. The median time to disease-related mortality was longer in patients who developed systemic metastases than in those who died of locoregional progression.
CONCLUSIONS: The mortality of patients with cSCC is mostly due to the regional progression of their lymphatic metastases. The appearance of distant metastases is practically always (96.9%) associated with previous lymphatic metastatic progression. Therefore, in the future, new studies will be needed to assess the regional management of cSCC in both surgical and adjuvant therapies.
Minocycline hydrochloride extended-release tablets are not bioequivalent to non-modified release minocycline products. Based on pharmacokinetic studies in healthy adults, Minocycline hydrochloride extended-release tablets produce a delayed Tmax at 3.5 to 4.0 hours as compared to a non-modified release reference minocycline product (Tmax at 2.25 to 3 hours). At steady-state (Day 6), the mean AUC(0-24) and Cmax were 33.32 mcg×hr/mL and 2.63 mcg/mL for minocycline hydrochloride extended release tablets and 46.35 mcg×hr/mL and 2.92 mcg/mL for minocycline hydrochloride capsules, respectively. These parameters are based on dose adjusted to 135 mg per day for both product.  
A single-dose, four-way crossover study demonstrated that Minocycline hydrochloride extended-release tablets used in the study (45 mg, 90 mg, 135 mg) exhibited dose-proportional pharmacokinetics. In another single-dose, five-way crossover pharmacokinetic study, Minocycline hydrochloride extended-release tablets 55mg,80 mg, and 105 mg were shown to be dose-proportional to Minocycline hydrochloride extended-release tablets 90 mg and 135 mg.  
When Minocycline hydrochloride extended-release tablets were administered concomitantly with a meal that included dairy products, the extent and timing of absorption of minocycline did not differ from that of administration under fasting conditions.  
Minocycline is lipid soluble and distributes into the skin and sebum.
Angiogenesis is mainly regulated by the delivery of VEGF-dependent signaling to cells. However, the angiogenesis mechanism regulated by VEGF-induced miRNA is still not understood. After VEGF treatment in HUVECs, we screened the changed miRNAs through small-RNA sequencing and found VEGF-induced miR-4701-3p. Furthermore, the GFP reporter gene was used to reveal that TOB2 expression was regulated by miR-4701-3p, and it was found that TOB2 and miR-4701-3p modulation could cause angiogenesis in an in-vitro angiogenic assay. Through the luciferase assay, it was confirmed that the activation of the angiogenic transcription factor MEF2 was regulated by the suppression and overexpression of TOB2 and miR-4701-3p. As a result, MEF2 downstream gene mRNAs that induce angiogenic function were regulated. We used the NCBI GEO datasets to reveal that the expression of TOB2 and MEF2 was significantly changed in cardiovascular disease. Finally, it was confirmed that the expression of circulating miR-4701-3p in the blood of myocardial infarction patients was remarkably increased. In patients with myocardial infarction, circulating miR-4701-3p was increased regardless of age, BMI, and sex, and showed high AUC levels in specificity and sensitivity analysis (AUROC) (AUC = 0.8451, 95 % CI 0.78-0.90). Our data showed TOB2-mediated modulation of MEF2 and its angiogenesis by VEGF-induced miR-4701-3p in vascular endothelial cells. In addition, through bioinformatics analysis using GEO data, changes in TOB2 and MEF2 were revealed in cardiovascular disease. We suggest that circulating miR-4701-3p has high potential as a biomarker for myocardial infarction.
Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour \[mL/hr\]).
Testicular cancer represents 1% of male neoplasms and 5% of all urological tumours. In 2021, 828 new patients in the Netherlands were diagnosed with testicular cancer. It is the most commonly diagnosed cancer among young men aged 20-39 years in the Netherlands and incidence is rising. Follow-up after treatment of testicular cancer consists of tumour marker assessment during hospital visits and multiple types of imaging at certain time points. Frequent hospital visits have significant impact on patients' lives, as in-hospital visits evoke distress around the time of visits. Home-based follow-up could be beneficial in terms of patients' well-being and societal cost-effectiveness. Furthermore, during the COVID-19 pandemic hospital visitations are minimized to decrease the chance of COVID-19 exposure. Home-based blood sampling will allow patients to stay home and avoid crowded areas such as public transport and the hospital.

Efforts to improve the current standard of follow-up in patients with testicular cancer should focus on ameliorating quality of life and cost-effectiveness. It provides an opportunity to support patients emotionally, to evaluate treatment effects and complications, and to inform them on their individual prognosis. This is especially true considering the growing importance of value-based healthcare and patient reported outcomes in medicine. The investigators therefore propose a patient-led home-based follow-up approach. This follow-up strategy primarily consists of tumour marker level monitoring at home and imaging performed in-hospital, but additional counselling/diagnostic testing remains possible if desired by patients. In this way the investigators hope to meet the individual needs of patients during follow-up and to improve quality of life outcomes, while achieving equal or greater societal cost-effectiveness.
PURPOSE:To enable obtaining of a new antibiotic substance KO-3988C, etc., with high activity and reduced side effects by culturing a microorganism, belonging to the genus Streptomyces and capable of producing the aforementioned antibiotic substance in a culture medium. CONSTITUTION:Streptomyces sp. KO-3988 (FERM P-10369) strain having the following properties is obtained by separating thereof from soil in ATAMI City in SHIZUOKA Prefecture. Morphological properties; linear aerial mycelium and cylindrical spore size of 1.4X1.9mum. Growth conditions; well growing on glucose nitrate agar and producing a soluble coloring matter. Growth temperature range; 15-35 deg.C. Utilizing D-glucose, etc., without utilizing raffinose, etc. The resultant strain in then aerobically cultured in a culture medium containing glucose, etc., at 20-37 deg.C and neutral pH for 3-6 days to afford a culture, which is subsequently centrifuged and extracted to produce in antibiotic substance KO-3988C or KO-3988H, expressed by formula I (R is group expressed by formula II to VII) and having antitumor activity.
Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
BACKGROUND: Pulmonary metabolic dysfunction can cause lung tissue injury. There is still no ideal drug to protect against hypoxia-induced lung injury, therefore, the development of new drugs to prevent and treat hypoxia-induced lung injury is urgently needed. We aimed to explore the ameliorative effects and molecular mechanisms of vitamin D3 (VD3) on hypoxia-induced lung tissue injury.
METHODS: Sprague-Dawley (SD) rats were randomly divided into three groups: normoxia, hypoxia, and hypoxia + VD3. The rat model of hypoxia was established by placing the rats in a hypobaric chamber. The degree of lung injury was determined using hematoxylin and eosin (H&E) staining, lung water content, and lung permeability index. Transcriptome data were subjected to differential gene expression and pathway analyses. In vitro, type II alveolar epithelial cells were co-cultured with hepatocytes and then exposed to hypoxic conditions for 24 h. For VD3 treatment, the cells were treated with low and high concentrations of VD3.
RESULTS: Transcriptome and KEGG analyses revealed that VD3 affects the complement and coagulation cascade pathways in hypoxia-induced rats, and the genes enriched in this pathway were Fgb/Fga/LOC100910418. Hypoxia can cause increases in lung edema, inflammation, and lung permeability disruption, which are attenuated by VD3 treatment. VD3 weakened the complement and coagulation cascade in the lung and liver of hypoxia-induced rats, characterized by lower expression of fibrinogen alpha chain (Fga), fibrinogen beta chain (Fgb), protease-activated receptor 1 (PAR1), protease-activated receptor 3 (PAR3), protease-activated receptor 4 (PAR4), complement (C) 3, C3a, and C5. In addition, VD3 improved hypoxic-induced type II alveolar epithelial cell damage and inflammation by inhibiting the complement and coagulation cascades. Furthermore, VD3 inhibited hypoxia-induced autophagy in vivo and in vitro, which was abolished by the mitophagy inducer, carbonyl cyanide-m-chlorophenylhydrazone (CCCP).
CONCLUSION: VD3 alleviated hypoxia-induced pulmonary edema by inhibiting the complement and coagulation cascades and autophagy pathways.
An insulin pump for use in conjunction with a mobile communication terminal capable of measuring a blood glucose level, and a network for transmitting control information for the insulin pump are disclosed. The insulin pump includes an external input port, an output port, memory, a key input unit, a control unit, and a motor driver. The external input port receives information on the amounts of insulin to be injected. The output port outputs information on the amounts of insulin injected. The memory stores the information on the amounts of insulin injected. The key input unit inputs the status of a user. The control unit extracts the information on the amounts of insulin to be injected from the memory. The motor drive operates a soft motor to supply insulin.
Participants in this group will follow standard of care treatment. Participants will be in this group for approximately 21 days.
NEW MATERIAL:The compound of formula I (R1 is 14-24C long-chain aliphatic acyl; R2 is 1-10C aliphatic acyl or aliphatic hydrocarbon group; NS is nucleoside residue) or its salt. USE:An antitumor agent. Since the compound has high solubility in aqueous solvent, it can be administered as an injection. It has remarkably excellent antitumor activity because of suppressed decomposition in living body. The compound has low toxicity and has metastasis-preventive and antiviral activities. PREPARATION:The objective compound can be produced by reacting a phospholipid derivative of formula II (X is choline residue) with a nucleoside of formula NS-OH (preferably 5-fluorouridine, etc.) in the presence of a phospholipase D-P in a solvent at 20-60 deg.C for 1-6hr. The reaction solvent is e.g. a two- layered solvent composed of an organic solvent such as chloroform and a buffer solution of 4-6pH.
Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
A kind of medicine preventing and treating hepatitis, belongs to the technical field of Chinese herbal medicine processing, uses Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Rhizoma Smilacis Chinensis, grass, Herba Hyperici Japonici, lion grass, Radix Stellariae Yunnanensis, Folium et Cacumen Artemisiae Halodendri seed and EM original solution etc. to be prepared from.All medicine compatibilities have become the damp and hot effect medicine stopping up Sheng excess syndrome icterohepatitis for the treatment of.Rhizoma Smilacis Chinensis expelling wind and removing dampness, removing toxicity for eliminating carbuncles diuretic damp eliminating heat, slow liver heavily fortified point kidney heavily fortified point muscles and bones, grass heat-clearing and toxic substances removing inducing diuresis for treating stranguria syndrome, the main damp and hot excess syndrome being jammed, blood stasis dispelling blood, profit three burnt benefit the five internal organs.Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. is inducing diuresis and reducing edema, has anti-inflammatory and antalgic treating the liver and the effect protected the liver, medicine oral administration and externally treatment hepatitis to be more beneficial for rehabilitation.Prevention effect is definite, inexpensive, draws materials easily, the most popular.
BACKGROUND: Depression and obesity are associated with impaired inhibitory control. Behavioral evidence indicates an exacerbating additive effect when both conditions co-occur. However, the underlying neural mechanisms remain unclear. Moreover, systemic inflammation affects neurocognitive performance in both individuals with depression and obesity. Here, we investigate additive effects of depression and obesity on neural correlates of inhibitory control, and examine inflammation as a connecting pathway.
METHODS: We assessed inhibitory control processing in 64 individuals with obesity and varying degrees of depressed mood by probing neural activation and connectivity during an fMRI Stroop task. Additionally, we explored associations of altered neural responses with individual differences in systemic inflammation. Data were collected as part of the BARICO (Bariatric surgery Rijnstate and Radboudumc neuroimaging and Cognition in Obesity) study.
RESULTS: Concurrent depression and obesity were linked to increased functional connectivity between the supplementary motor area and precuneus and between the inferior occipital and inferior parietal gyrus. Exploratory analysis revealed that circulating inflammation markers, including plasma leptin, IL-6, IL-8, and CCL-3 correlated with the additive effect of depression and obesity on altered functional connectivity.
LIMITATIONS: The observational design limits causal inferences. Future research employing longitudinal or intervention designs is required to validate these findings and elucidate causal pathways.
CONCLUSION: These findings suggest increased neural crosstalk underlying impaired inhibitory control in individuals with concurrent obesity and depressed mood. Our results support a model of an additive detrimental effect of concurrent depression and obesity on neurocognitive functioning, with a possible role of inflammation.
Studies at the NIH Clinical Center have shown that intermittent pulse cyclophosphamide therapy is effective for treating patients with severe lupus nephritis, but may result in substantial rates of sustained amenorrhea. Initial studies in patients with autoimmune rheumatic diseases have also suggested a beneficial effect from the lymphocyte-specific nucleoside analogs chlorodeoxyadenosine and fludarabine. Cyclophosphamide induces DNA cross-links whereas, nucleoside analogs inhibits DNA repair indicating complementary and partially synergistic modes of action. Whether combination of lower doses of cyclophosphamide with nucleoside analogs will increase efficacy while at the same time minimize toxicity from higher-cumulative doses of cyclophosphamide has not been determined. In this phase I/II study, 15 patients with proliferative lupus nephritis will be treated as outpatients with a combination of oral cyclophosphamide (500 mg/m(2)) on day 1 followed by fludarabine (30 mg/m(2)) subcutaneously on days 1, 2 and 3 every month for 3 cycles. The cumulative dose of cyclophosphamide in this regimen is approximately 2.5g as compared to greater than or equal to 30g in the standard NIH cyclophosphamide regimen. In this study the tolerance and toxicity of this combination will be studied. Regeneration of T and B cells following depletion including analysis of antigen-repertoire and function will also be examined. Preliminary efficacy information, including rates and time to renal remission and rates of preservation of renal function, will be analyzed to be used for future controlled studies. Pharmacokinetic analysis will be performed on a subset of patients to determine the bioavailability and pharmacokinetic parameters of subcutaneous fludarabine.